This PubMed-indexed report presents a sex-stratified analysis from the SMART-CHOICE 3 trial comparing clopidogrel monotherapy with aspirin monotherapy in patients after percutaneous coronary intervention (PCI). The article is published in EuroIntervention (2026 Sep 21;22[18]:e990–e1000) and is identified as a Randomized Controlled Trial in the PubMed entry. Bibliographic identifiers include PMID 42765401 and DOI 10.4244/EIJ-D-26-00332.
The PubMed entry classifies the work as a Randomized Controlled Trial and the specific analysis reported is sex-stratified, meaning outcomes were examined separately for females and males. Beyond these design descriptors appearing in the title and indexing fields, the provided source excerpt does not include the abstract text or detailed methodological information (for example, randomization method, sample size, follow-up duration, or endpoint definitions).
The title specifies the comparison of clopidogrel monotherapy versus aspirin monotherapy following PCI. The PubMed record makes clear that the study focused on monotherapy with either antiplatelet agent after the interventional procedure. The excerpt does not provide dosing regimens, timing of monotherapy initiation relative to PCI, or details about any preceding dual antiplatelet therapy (DAPT) protocols.
The key analytic feature called out in the title is the sex-stratified approach — the investigators report comparisons separately for females and males. The PubMed snippet confirms this analytic intent but does not present numerical results, subgroup sizes, subgroup-specific event rates, interaction testing, or other statistical outputs necessary to interpret whether treatment effects differed by sex.
The article lists a large multi-center author group led by Woochan Kwon and numerous coauthors. Affiliations cited in the PubMed entry are predominantly South Korean institutions, including Kangbuk Samsung Hospital, Samsung Medical Center, Chungnam National University Hospital, The Catholic University of Korea hospitals, and multiple university medical centers across Korea. The work is reported on behalf of the Smart-Choice Investigators.
Available bibliographic details from the PubMed entry:
These identifiers facilitate retrieval of the full text for complete methodological and results review.
The PubMed page content provided here contains title, authors, affiliations, journal citation, and indexing metadata but does not include the article abstract or full-text content. Consequently, the following key study elements are not reported in the source excerpt and cannot be summarized:
Because these items are absent from the PubMed excerpt, no efficacy, safety, or subgroup conclusions can be drawn from the provided source alone.
From the bibliographic information and title, clinicians can recognize that the SMART-CHOICE 3 randomized trial specifically evaluated antiplatelet monotherapy strategies after PCI with a planned focus on sex differences. However, to inform clinical practice or guideline-relevant interpretation, clinicians and researchers should access the full EuroIntervention article to review the complete methods and results. The full text will be necessary to:
Until the full article content is reviewed, clinicians should not change antiplatelet prescribing practices based solely on the PubMed citation. The PubMed record provides the citation and indexing details necessary to obtain the complete report for detailed appraisal.
Note: This rewrite preserves only the information available in the provided PubMed excerpt. Specific numerical results, endpoint data, and the authors’ conclusions were not reported in the source material supplied and therefore are not included here. For definitive data and interpretation, consult the full EuroIntervention publication (DOI 10.4244/EIJ-D-26-00332).